Literature DB >> 6101155

Nitroglycerin pharmacokinetics after intravenous infusion in normal subjects.

E F McNiff1, A Yacobi, F M Young-Chang, L H Golden, A Goldfarb, H L Fung.   

Abstract

The purpose of this investigation was to examine the pharmacokinetics of nitroglycerin in normal volunteers after intravenous drug administration. Eight subjects (including one subject on two occasions) received a dose of approximately 0.6 mg iv of nitroglycerin at a rate of 18 micrograms/min. Plasma concentrations of intact drug during and after the infusion were determined using a GLC method. Intra- and intersubject variability in nitroglycerin plasma kinetics was substantial. Generally, however, plasma nitroglycerin disposition was characterized by: (a) a large apparent plasma clearance (0.3-1 liter/min/kg), (b) a large volume of distribution (approximately 3 liters/kg), and (c) a rapid plasma half-life (approximately 3 min). From the apparent volume of distribution obtained, plasma drug can be estimated to account for only approximately 1.3% of total drug in the body. Minor fluctuations in tissue distribution, which can be produced by a myriad of external and internal stimuli, could cause dramatic fluctuation in plasma nitroglycerin concentrations and, hence, in the calculated pharmacokinetic parameters. For example, in two subjects studied, plasma nitroglycerin concentrations oscillated to such an extent that pharmacokinetic analysis could not be performed. In some subjects, steady-state concentrations were not observed in spite of the apparent short plasma half-life, and rebound in plasma concentrations during the postinfusion phase were evident. These phenomena were also observed in other kinetic studies involving organic nitrates.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6101155     DOI: 10.1002/jps.2600700923

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  23 in total

1.  Heating and cooling of the nitroglycerin patch application area modify the plasma level of nitroglycerin.

Authors:  T O Klemsdal; K Gjesdal; J E Bredesen
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Is there counter-current exchange of drugs in limbs after percutaneous absorption?

Authors:  J F Hecker
Journal:  Clin Pharmacokinet       Date:  1989-09       Impact factor: 6.447

3.  Transdermal bioavailability and first-pass skin metabolism: a preliminary evaluation with nitroglycerin.

Authors:  E Nakashima; P K Noonan; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1987-08

Review 4.  Pharmacokinetics of various preparations of organic nitrates.

Authors:  J P Kampmann
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 5.  Intravenous glyceryl trinitrate (nitroglycerin). A review of its pharmacological properties and therapeutic efficacy.

Authors:  E M Sorkin; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1984-01       Impact factor: 9.546

Review 6.  Nitrate tolerance. A review of the evidence.

Authors:  J T Flaherty
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

7.  Variable glyceryl dinitrate formation following infusions of glyceryl trinitrate at different vascular sites in the rat.

Authors:  E Nakashima; D T Lau; L Z Benet
Journal:  Pharm Res       Date:  1991-07       Impact factor: 4.200

8.  Steady state pharmacokinetic haemodynamic studies of intravenous nitroglycerin in congestive cardiac failure.

Authors:  P W Armstrong; D G Watts; J A Moffat
Journal:  Br J Clin Pharmacol       Date:  1983-10       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of organic nitrates.

Authors:  M G Bogaert
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

10.  Concentrations of isosorbide dinitrate, isosorbide-2-mononitrate and isosorbide-5-mononitrate in human vascular and muscle tissue under steady-state conditions.

Authors:  W Schneider; G Menke; R Heidemann; P Satter; M Kaltenbach; N Rietbrock
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.